```
1
   2
   3
                 Clinical, immune and genetic risk factors of malaria-
   4
                 associated acute kidney injury in Zambian Children: A study
   5
                 protocol
   6
   7
   8
                 Chisambo Mwaba<sup>a,b*¶</sup>, Sody Munsaka<sup>c &</sup>, David Mwakazanga<sup>d,&</sup>, David Rutagwerae,<sup>e, &</sup>
   9
                 Owen Ngalamika<sup>f, &</sup>, Suzanna Mwanza<sup>g, &</sup>, Mignon McCulloch<sup>h, &</sup>, Evans
10
                 Mpabalwani<sup>a,b, &</sup>
11
12
13
14
                  Author Affiliations:
15
                              a. Department of Paediatrics and Child Health, School of Medicine, University of
16
                                        Zambia. P.O. Box 50110, Lusaka, Zambia.
17
                             b. Department of Paediatrics, University Teaching Hospitals- Children's Hospital.
18
                                        Lusaka, Zambia. Private Bag RW1X, Nationalist Road. Lusaka, Zambia.
19
                             c. Department of Biomedical Sciences, School of Health Sciences, University of
20
                                        Zambia. P O Box 50110, Lusaka, Zambia
21
                             d. Public Health Department, Epidemiology and Statistics Unit, Tropical Diseases
22
                  NOTE: This Reprint reports new restard that has not being on the loss of being reprint the loss of the
23
```

24	e.	Kaposi's Sarcoma Molecular Laboratory, Paediatric Centre of Excellence,
25		University Teaching Hospitals- Children's Hospital
26	f.	Dermatology and Venereology Division, Department of Internal Medicine,
27		University Teaching Hospital, University of Zambia School of Medicine, Lusaka,
28		Zambia.
29	g.	Department of Paediatrics and Child Health, Chipata Central Hospital, Chipata,
30		Zambia.
31	h.	Division of Paediatric Nephrology, Red Cross War Memorial Children's Hospital,
32		University of Cape Town, Rondebosch 7700. Cape Town, South Africa.
33		
34		
35	* Corre	esponding Author
36	Chisam	bo Mwaba, Department of Paediatrics and Child Health, University of Zambia School
37	of Med	icine, P.O. Box 50110, Lusaka, Zambia. <u>chisambo.mwaba@unza.zm</u>
38		
39		
40	¶These	authors contributed equally to the work.
41	& Thes	e authors also contributed equally to the work.
42		
43	Fund	ding

C.M received a PHD scholarship from the Ministry of Technology and Science of Zambia. 44

45

46 Competing Interests

47 The authors have no competing interests to declare.

48

49 **Data Availability**

50 All relevant data has been presented in the manuscript and its associated files.

51

52 Abstract

53 Background

Acute kidney injury (AKI) affects nearly half of children with severe malaria and increases the 54 55 risk of adverse outcomes such as death and poor cognitive function. The pathogenesis and predictors of malaria- associated acute kidney injury (MAKI) are not fully described. This 56 57 study aims to determine the clinical, immune, and genetic correlates of risk to AKI in Zambian children admitted with malaria. In addition, we intend to assess a modified renal angina index 58 (mRAI), kidney injury molecule - 1 (KIM-1), neutrophil gelatinase-associated lipocalin 59 (NGAL)) and soluble urokinase receptor (suPAR), when done on the first day of admission, 60 for ability to predict AKI 48 hours later (day 3) in children admitted with malaria. 61

62 Methods

63 This is an unmatched case-control study, with a case to control ratio of 1:1, in which 38064 children with malaria and aged less than 16 years are being recruited from two hospitals in

65 Zambia. Eligible children are recruited after obtaining written informed consent. Recruitment began 6th March,2024 and will continue until July 2025. AKI is defined using the 2012 KIDGO 66 AKI creatinine criteria and cases are defined as children admitted with malaria who develop 67 AKI within 72 hours of admission while controls are children admitted with malaria but with 68 no AKI. Serum creatinine is collected on day 1 within 24hours of admission and then again on 69 Day 3 post admission. Baseline biomarker concentrations will be determined using the 70 Luminex multiplex Elisa system or high-sensitivity ELISA. SPSS version 29 will be used for 71 data analysis. Descriptive statistics and inferential statistical tests will be run as appropriate. A 72 73 $p \le 0.05$ will be considered as significant. The utility of the renal angina score for predicting MAKI will be assessed using sensitivity, specificity, and estimates of the area under the curve 74 (AUC). 75

- 76
- 77
- 78

79 Keywords

Acute kidney injury (AKI); Risk factors; AKI risk prediction; Malaria-associated acute kidney
injury (MAKI); Endothelial activation; Children; Oxidative stress; Renal Angina Index;
Zambia.

83

84 **1.0 Introduction**

85 1.1 Background

Worldwide, malaria is still responsible for nearly a quarter of a million under-five deaths 86 annually and although Zambia contributes a mere 1% to total worldwide cases, malaria is the 87 leading cause of mortality in the country. [1, 2, 3] Many of these deaths are attributable to the 88 development of organ dysfunction including acute kidney injury (AKI). AKI which manifests 89 in approximately 10-50% of children with malaria, increases the risk of mortality sixfold, and 90 its long-term adverse effects include impaired cognitive function and chronic kidney disease 91 92 (CKD).[4, 5, 6, 7, 8] At Lusaka's University Teaching Hospitals-Children's Hospital (UTH-CH), malaria stands as the predominant cause (60%) of AKI in children undergoing dialysis, 93 94 with nearly 20% of these cases progressing to CKD.[9] The development of CKD and endstage kidney disease (ESKD) in these patients, is life-limiting due to constraints in access to 95 kidney replacement therapy and transplantation.[10] Yet despite this state of affairs, the 96 epidemiology, immune and genetic risk factors of MAKI are incompletely described in our 97 population. 98

In MAKI, risk factors may be classified as clinical or biological-various biological molecules involved in mechanisms such as cytoadherence, immune dysregulation, heme nephrotoxicity and increased oxidative stress that are involved in MAKI pathogenesis.[6, 7, 11, 12, 13] The importance of any particular risk factor in any given population may be modulated by peculiarities in local medical practice, access to healthcare resources, social determinants of health, changing malaria transmission intensity patterns and the effect of genetic variability on the function of the various immune molecules that are involved in MAKI pathogenesis.

106 Children with malaria are at increased risk of dehydration because they often present with 107 excessive fluid losses resulting from diarrhea, vomiting, increased insensible water losses and 108 reduced ability to ingest fluids due to poor appetite, nausea, or decreased levels of 109 consciousness that may accompany the illness. Conroy et al found that a urea/creatinine ratio 110 consistent with pre-renal AKI was prevalent in children with MAKI.[14] Other investigators

have reported comparable findings with the presence of shock being more likely in children with MAKI [15] The effect of fluid losses on the kidney may be further worsened by limited access to appropriate level of health care, cultural practices such as seeking out traditional treatments prior to presentation and use of nephrotoxins such as herbal medications and aminoglycosides. [15,16]

Another potential biological nephrotoxin is the oxidant, cell free haemoglobin. [4, 13, 17, 18] Elphinstone et al showed that the haem/hemopexin ratio was higher in paediatric malaria patients with stage 3 AKI compared to those without.[19] Similarly increased serum markers of hemolysis (bilirubin, lactate dehydrogenase) have been shown to correlate to greater odds of MAKI.[15] This is of particular concern in patient populations who may already have excessive intravascular haemolysis from underlying hemolytic genetic defects or indeed malaria patients with an increased parasite load (pfHRP2) who are at risk of greater haemolysis.

It is thought that vascular obstruction resulting from red cell sequestration in the renal 123 circulation contributes to compromised microvascular perfusion which in turn may contribute 124 to MAKI pathogenesis.[6,13] Plasmodium falciparum generates a cell-surface molecule 125 known as PfEMP1, which facilitates the adhesion of infected red cells to endothelial cells in a 126 process known as sequestration.[20,21] Various studies have shown a link between heightened 127 sequestration and parasite load to higher risk of MAKI. Indirect evidence includes a correlation 128 129 between markers of heightened sequestration such as *Plasmodium falciparum* histidine-rich protein 2 (*Pf*HRP2) and MAKI, while more direct evidence has been drawn from a few human 130 autopsy studies and experimental animal models.[15, 22, 23, 24] Additionally, cytoadherence 131 leads to endothelial activation which in turn leads to worsening cytoadherence which results 132 into a vicious cycle in which worsening cytoadherence begets endothelial activation and vis 133 versa.[11, 13, 25] Some studies have found that increased markers of endothelial activation, 134

increased circulating soluble cell adhesion molecules as well as increased monocyte activation
are linked to greater risk of organ dysfunction including MAKI .[26, 27, 28, 29, 30]

Furthermore, polymorphisms in the genes coding for these various immune molecules may influence gene function with resultant alteration in amounts or function of the gene products.[31, 32] Numerous studies have suggested a link between immune molecule gene polymorphisms with various severe malaria syndromes.[33, 34, 35, 36] However, most of these studies lacked statistical power to detect associations with MAKI due to heterogeneous samples encompassing various forms of severe malaria.

There is limited data evaluating the utility of these various immune molecules, or indeed the 143 144 numerous emerging AKI biomarkers such as kidney injury molecule – 1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL) and soluble urokinase receptor (suPAR), in prediction 145 of MAKI.[37, 38] Additionally, although some clinical prediction rules such as the Renal 146 Angina Index (RAI) have been formulated, these have mostly been tested in general paediatric 147 intensive care unit (PICU) populations and have not been validated in children with 148 malaria.[39] RAI utilizes risk factors for AKI and early clinical signs of kidney injury to create 149 a composite score with a score greater than 8 out of 40 being predictive of increased AKI 150 risk.[39] 151

We hypothesize that various clinical factors, serum concentration of immunological molecules, as well as genetic polymorphisms of selected immune factors are correlated to the risk of developing AKI in children admitted with malaria and can therefore be used for risk prediction in MAKI. Specifically, we hypothesize that 1)delayed access to care, hyperparasitaemia, increased oxidative stress, presence of exaggerated haemolysis and dehydration increase the risk of MAKI, 2) that MAKI is associated with higher concentrations cytokines or serum markers of endothelial activation, 3) that the Renal Angina Index, NGAL, suPAR and KIM-1

when used in severe malaria may be useful in predicting severe AKI at 48 hours and 4) that ten (10) immune molecule single nucleotide gene polymorphisms (SNPs) are associated with an altered risk of AKI in children admitted for malaria.

The purpose of this study is to 1) to determine the correlation between clinical risk factors 162 (hyperparasitaemia, delayed access to care, urea/creatinine ratio> 20, increased oxidative 163 stress, increased serum bilirubin and low haemoglobin) and MAKI, 2) determine the 164 correlation between plasma pro- and anti-inflammatory cytokine concentrations and MAKI, 3) 165 to assess the relationship between ten (10) immune molecule gene polymorphisms namely 166 interleukin (IL)-10 (rs1800871, rs1800871), tumor necrosis factor-alpha (TNF-α) (rs361525, 167 rs1800629), Type I Interferon alpha receptor 1 (IFNAR1) (rs2843710, rs2243594), haem-168 oxygenase-1(HMOX1) (rs7285877), nitric oxide synthetase 2(NOS2), Transforming growth 169 factor beta-2 (TGF-Beta 2) (rs4846478) and toll-like receptor- 4(TLR4) (rs4986791) and the 170 MAKI phenotype, 4) to determine the utility of the Renal Angina Score in predicting MAKI 171 and access whether its modification with population specific predictors will lead to enhanced 172 performance and finally, 5) to determine the predictive value of novel biomarkers (NGAL, 173 suPAR, KIM-1) in MAKI. We hope that the proposed work will provide evidence that will 174 improve early diagnosis of MAKI and consequently result into adoption of protocols that 175 promote the institution of remedial treatments and referral of children in a timelier manner. 176

177

2.0 Materials and methods

179 **2.1 Study design**

The project is divided into two sub-studies namely 1) Sub-study 1 which answers objectives 1,
2 and 3, and is an unmatched case-control study with a case: control ratio of 1:1. An unmatched

design was chosen because this is an exploratory study however during analysis of data for the immune molecules patients will be analysed based of age groups. Sub-study 2 answers objectives 4 and 5 and is a nested prospective observational study that recruits participants from the control arm of sub-study 1 (Fig1).

186





This is a case-control study with a nested prospective observational study. Participant serum creatinine will be determined on Day 1 and on Day 3. Patients meeting KDIGO AKI creatinine criteria will be classified as cases while those who do not meet the KDIGO creatinine AKI criteria will be classified as controls. The nested prospective observational study draws its study population from the cohort of malaria patients with absent AKI on day l. serum creatinine will be repeated on day 3 in order to determine if KDIGO stage 2/3 (severe) AKI will have developed on Day 3.

195

196 2.2 Study setting

The study participants are drawn from Chipata Central Hospital (CCH) in Chipata town of the
Eastern province of Zambia and from the University Teaching Hospitals Children's Hospital
(UTHs-CH) in the capital city of Zambia, Lusaka.

Chipata town is located about 600 km from Lusaka and is the provincial capital of the Eastern 200 province which is a medium malaria transmission zone (parasite prevalence among children in 201 Eastern Province is 21%).(40) Most cases of malaria occur in the first six months of the year 202 (seasonal transmission).(40) CCH is a tertiary hospital with the four major specialties of 203 204 paediatrics, internal medicine, surgery and obstetrics and gynecology available. The hospital 205 has a capacity of 500 beds and is an internship-training site and fellowship-training site for all the above-mentioned specialties. The paediatrics department has a capacity of 70 beds with 206 access to level II intensive care unit (ICU) that admits neonates, children and adults with both 207 medical and surgical conditions The paediatrics department has a capacity of 70 beds with 208 access to level II mixed intensive care unit (ICU). The selection of this site was based on a 209 prior study conducted at UTH, revealing that CCH ranked as the second most frequent hospital 210 referring children with MAKI for treatment at UTHs-CH, nephrology unit. Additionally, the 211 chosen site provides robust support for the study. The site has good laboratory support 212 including the presence of an ultra-low freezer (-80°C) and capacity to conduct PCR. 213

The UTH-CH is the leading tertiary paediatric hospital in Zambia, located in Lusaka district, 214 which is a very low Malaria transmission zone.[40] The hospital receives referrals from across 215 the country and has the older and larger of the two pediatric dialysis centers in the country. The 216 hospital has a capacity of 350 beds. The nephrology unit evaluates about 300 children per year 217 and a third of these have AKI. The site was chosen to capture the more severe forms of MAKI 218 that tend to be referred from across the country. The site has access to molecular laboratories 219 220 including Kaposi's Sarcoma (KS) molecular laboratory with subzero freezers, PCR machines, sequencers, flow cytometer, facilities for gel electrophoresis and staff trained in these 221 222 techniques.

223

224 **2.3 Study population**

Children aged less than 16 years who are admitted for malaria (modified CDC 2014 definition)
at the UTHs-CH and CCH constitute the target population. Recruitment began 6th March,2024
and will continue until July 2025. For sub-study 2, the nested prospective observational study,
the study population is drawn from the cohort of malaria patients with no AKI on day 1 (Fig 1).

229

230 2.3 Inclusion and exclusion criteria

To be included in the study a child has to be between 6 months and 16 years old, have parasitological evidence of malaria and be admitted to either UTHs-CH or CCH. The upper age limit for admission to the pediatric services at the two hospitals is 16 years.

Children who are known to have CKD and children who have received dialysis prior to
admission for the episode of AKI are excluded. Dialyzed patients are excluded because serum
levels of various biomarkers may be distorted during dialysis.

237

238 2.4 Study definitions

Any child with history of fever exhibiting signs or symptoms consistent with malaria (fever, chills and sweats, headaches, muscle pains, nausea, vomiting, fatigue, anemia, coma, seizures, focal neurological signs, respiratory distress) who shows evidence of plasmodium infection by a)Detection of malaria by rapid diagnostic antigen (RDT) testing without confirmation by microscopy or nucleic acid testing e.g., in this study.[41] OR b) Detection of parasites by microscopy on blood films will be defined as having <u>malaria</u>.

In areas of high malaria endemicity a positive slide, RDT or even presence of positive nucleic acid test does not definitively prove that a patient has clinical malaria as many children may have asymptomatic infection along with other conditions that could explain the clinical presentation.[42, 43]

A child aged 6 months to 16 years old who meets the KIDGO 2012 AKI criteria and who has malaria as per the modified CDC malaria case definition is categorized as having <u>MAKI</u>. <u>A</u> case <u>is</u> a child 6 months old to 16 years of age with MAKI detected within the first three days of admission while a <u>control</u> is defined as a child aged 6 months to 16 years of age with malaria but with NO MAKI within the first three days of admission.

254

255 2.5 Sample size estimation and sampling methods

The study plan is to recruit a total of 380 patients, with 190 being case while 190 will be controls. A rate of 10% for missing data is factored in. This sample size will provide 80% power, with a statistical significance of 5%, to detect an effect sizes equivalent to those reported in previous studies. [14, 15, 44, 45, 46, 47, 48, 49, 50, 51, 52] Supplementary information (S1 effect sizes and estimation of sample size) provides details for both sub-study 1 and sub-study
2. This is an exploratory study therefore no matching of cases to controls will be conducted at
recruitment. However, during laboratory analysis of the various immune molecules 100 cases
will be matched to 100 controls based on age groups (less than 5 years, 5-10 years and greater
than 10 years) with 20 children assigned to each age group for both cases and controls, in order
to account for the well-known effect of age on immune molecule serum concentrations.
Consecutive sampling is being used.

267

268 **2.6 Sub-study 1**

269 2.6.1 Sub-study 1 Recruitment Procedure

270 Screening of children with malaria is conducted by the study nurse. The purpose of the study 271 is explained to the legal guardians or parents of all potential participants. Written informed consent and assent (children > 8 years if fully conscious) where appropriate, is obtained after 272 explaining the purpose of the study to potential participants. The Information sheet, consent, 273 and assent forms are available in the predominant languages of these regions, namely English, 274 Bemba, Nyanja, and Tonga, and are administered according to the preferred language of 275 276 communication chosen by potential participants. Each participant is then assigned a unique study number. A pre-designed data collection form on Redcap TM is used to collect participant 277 demographic and clinical data. 278

279 Children are recruited from both study sites. The recruitment procedure is illustrated in Fig 1. 280 The Case definition of MAKI is development of AKI (KDIGO 2012 criteria) within the first 281 three days of admission. The patient's creatinine is collected at recruitment (Day 1, within the 282 first 24 hours of admission) as well as on Day 3 of admission. Malaria patients meeting 283 definition of MAKI based on creatinine result collected at recruitment on day 1 or on day 3 are

assigned into the case arm of the study. Malaria patients who do not meet definition of MAKI
based on serum creatinine result from samples collected on day 1 and on day 3 are assigned
into the control arm of the study. Additionally, all children referred to the study site with a
diagnosis of MAKI already made are also recruited as cases after confirmation of blood results
at the study site.

Specimens for serum urea, bilirubin, potassium, sodium, haemoglobin, and platelet count are also collected. Finally, also being collected at baseline are specimens for kidney biomarkers, cytokines, adhesion molecules, pfHRP2 and malondialdehyde (MDA).

Venous blood aliquot, which is computed based on the child's age and weight, is drawn, 292 ensuring that the amount for any single blood draw does not exceed the maximum allowable 293 294 volume, set at 2.5% of the total blood volume, following widely used guidelines for both 295 clinical and research purposes.[53] The collected whole blood is placed in heparinized vacutainer, 2 EDTA vacutainer and in a plain tube. The specimen in the plain tube vacutainer 296 297 will be left at room temperature for 10 minutes to facilitate clot formation. Subsequently, this sample undergoes centrifugation at 3000 rpm for at for 5 minutes, after which the supernatant 298 is stored at -80°C. The sample in the heparinized container similarly undergoes centrifugation 299 at 3000 rpm for 5 minutes. The supernatant is also stored in a cryovial and stored at -80 °C for 300 onward transport and processing at UTH-CH. 301

302

303 2.6.2 Sub-study 1 Laboratory procedure

All the specimens kept at -80 °C are transported to the UTH-CH on dry ice for analysis. The Beckman Coulter AU 480 analyser will be employed to assess blood parameters, including creatinine, sodium, potassium, bilirubin and urea as per manufacturer instructions. Blood

307 platelet count and haemoglobin are determined at each respective study site using the Sysmex308 XT 4000i haematology analyser.

To conduct the cytokine analysis the frozen serum will be thawed. A Bead based multiplex assay (cytometric bead array) will be done on a LuminexTM platform, at the KS molecular laboratory, at UTH-CH, will be used to analyze the serum cytokine concentrations. The manufacturer's protocol will be followed to run the assay.

A calibration curve for calculating the concentration of cytokines will be created using the 313 manufacturer's provided lyophilized standards in the kits, and the cytokine concentrations in 314 samples will then be deduced from standard curves. Because immunoassays generate a 315 sigmoid-shaped curve, logistic regression mathematical modelling is used to allow curve fitting 316 beyond the linear range of the curve. This facilitates subsequent determination of the Y-317 intercept and gradient. The lower limit of detection for the various cytokines will be 318 determined. If readings are above the upper limit of detection, dilutions of 1:4, 1:8, 1:16 and 319 so on will be done until a negative result, then the dilution factor will be used to determine the 320 actual concentration.[49] 321

For quantification of oxidative stress, the MDA NWLSSTM malondialdehyde assay will beused. All the laboratory analytes in this study are shown in Table 1.

324

325

Table 1: Study analytes

Biomarker	Specimen	Test	
Interleukin 18	Plasma	Cytometric bead array	
Interleukin 1		5	
Interleukin 10			
Interleukin 6			
Interleukin 12			
Soluble TNF-α			
IFN-γ			
Angiopoietin 1	Plasma	Cytometric bead array	

Angiopoietin 2 Endothelial cell protein C receptor (EPCR). ICAM-1, VCAM		
MDA	Plasma	MDA NWLSSTM malondialdehyde assay (commercial oxidative stress kits)
pfHRP2	Blood	ELISA

326

Twelve polymorphic markers are proposed for investigation in this study. They have been chosen based on previous associations in the literature to other forms of severe malaria or other AKI phenotypes with a postulated similarity in pathophysiology to MAKI.

330 Whole blood is collected onto special filter paper cards as dried blood spots for later genomic DNA extraction.[54] Genomic DNA will be extracted using a commercial DNA purification 331 kit (QIAwave DNA Blood and Tissue Kit by Qiagen TM). Polymerase Chain Reaction (PCR) 332 will be used for DNA amplification. We will use primers as described in previous experiments 333 and for those SNPs where we could not find references in the literature, we searched NCBI 334 335 gene to obtain information on the location of the target then we obtained the sequence of the area of interest in FASTA format and used the NCBI primer tool to design appropriate primers. 336 The QiagenTM Multiplex PCR kit (cat no.206143) and primers (S2 List of primer sequences), 337 and restricting enzymes for the 12 gene polymorphisms will be placed in a thermal cycler as 338 per manufacturer protocol. Gel electrophoresis will then be conducted to determine the 339 340 presence of the SNPs of interest, then for positive samples the PCR products will be purified using a commercial kit, before subjecting them to Sanger sequencing (ABI 3500) at the School 341 of Veterinary Medicine genomics laboratory, University of Zambia. 342

343

344 2.6.3 Sub-study 1 variables

The study collects information on occurrence of MAKI in admitted malaria patients as the primary outcome variable. Serum creatinine is collected at discharge or if the patient is still hospitalized on day 7 to establish the renal outcome. Renal outcome is noted as a secondary outcome. Outcome is classified as normal renal function if eGFR is >120ml/1.73m2/min or abnormal for eGFR < 120ml/1.73m2/min. The Schwartz formula is used to estimate GFR.

The three categories of independent variables for this proposed study are socio-demographic, clinical, and laboratory variables. Socio-demographic factors encompass the patient's age, gender, place of residence (village/suburb), distance from the referring facility, the referring health facility, province of origin, and self-identified ethnic group. Ethnic group data is being collected for analyzing genetic information among participants.

Clinical independent variables include patient height/length, weight, hydration status 355 356 (classified according to WHO as none, some, and severe)[55], vital signs (blood pressure, oxygen saturation, presence of edema), and Glasgow Coma Score upon admission. Additional 357 358 clinical variables being collected include the reason for referral, identification of AKI at the referring facility, date of AKI identification if applicable, history of anuria/oliguria, and pre-359 admission seizure history. Other clinical variables comprise duration of illness before 360 admission, pre-admission medications and dosages, family history of renal disease, the patient's 361 past medical history, and the number of blood transfusions in the current illness. Additionally, 362 363 birth weight, Length of hospital stay, admission to and duration of admission to PICU, mortality, are documented. 364

Laboratory independent variables are the admission creatinine, admission estimated glomerular filtration rate (GFR), hemoglobin electrophoresis, admission hemoglobin, bilirubin, platelet count, and random blood sugar (RBS). Routine HIV testing is conducted for all pediatric patients upon admission, following an opt-out system for caregivers. Recorded HIV test results

in the patient file are documented. Further laboratory results on admission include PfHRP2
levels, cytokine levels (IL-18, IL-1, IL-10, IL- 12, Soluble TNF-α, IFN-γ), adhesion molecule
levels (Ang-1, Ang-2, EPCR, ICAM-1, VCAM), and markers of oxidative stress (MDA).

372

373 2.6.4 Sub-study 1 data analysis

Patient data will be analyzed utilizing IBM SPSS Statistics version 29 (IBM Corp., Armonk, NY, USA). Categorical variables will be presented as frequencies and percentages. For continuous variables, those with asymmetric distributions will be reported as medians and interquartile ranges (IQRs), while those with normal distributions will be presented as means and standard deviations (SDs). The normality of continuous data will be assessed using the Shapiro-Wilk test.

To assess the strength of associations between various categorical exposure variables and the outcome (AKI), the chi-square test will be employed. In cases where any cell in the contingency table contains fewer than five expected observations, the Fisher's Exact test will be used.

For the association of normally distributed continuous variables, the independent t-test will be applied to compare means between the two groups. Non-normally distributed continuous data will undergo non-parametric testing, such as the Mann-Whitney U test or the Kruskal-Wallis test. Multivariate logistic regression will be conducted to address potential confounding factors. All statistical tests will be two-tailed, and a significance level of $p \le 0.05$ will be considered statistically significant.

Analysis of immune molecule data will be conducted using GraphPad Prism software (Version
9, San Diego, CA, USA). Cytokine data will be represented as geometric means with a 95%
confidence interval (CI) to illustrate the central tendency of cytokine levels. Significant

differences between cases and controls will be assessed using either the t-test or the Mann-Whitney U test.

To evaluate the discriminatory power of each immune molecule between cases and controls, a Receiver Operator Curve (ROC) will be constructed. Multiple logistic regression analyses for each cytokine/adhesion molecule will be carried out to compare cases versus controls. The goodness of fit for the model will be assessed using the Hosmer-Lemeshow test.

The level of association of the various polymorphisms to MAKI will be determined. The clinical and demographic composition of the cases and controls will be compared using the Chi-square test or Fischer's Exact test. The level of correlation of the two groups to the presence of the SNPs of interest will be done using Chi-square and Fisher's exact tests. All loci will be assessed for the presence of Hardy–Weinberg equilibrium. A P-value of <0.05 will be considered statistically significant.

404

405 **<u>2.7 Sub-study 2 (Nested prospective cohort study)</u></u>**

406 2.7.1 Sub-study 2 Recruitment Procedure

407 This is a nested study utilizing a prospective observational study. Recruitment is conducted as shown in Fig 1. Written informed consent and assent where appropriate are obtained after 408 explaining the purpose of the study to potential participants as described in sub-study 1. 409 Baseline scoring of the renal angina index (Table 2) within the first 24 hours after admission 410 using a pre-designed data collection form is done. Fluid overload is determined as the 411 412 difference in body weight at recruitment and at admission to hospital divided by the weight at admission to hospital expressed as a percentage. [56] The patient baseline creatinine is collected 413 at admission as described under the methods section for sub-study 1. The KDIGO 2012 414

- 415 creatinine criterion is used to define AKI and severe AKI is defined as KIDGO 2012 stage 2
- 416 and 3 AKI as per previous studies.

417

418 Table 2: The renal angina score

RAI= Risk X Injury											
(score ranges from 1-40)											
INJURY			RISK FACTOR								
% Drop in	% FO	Score		Score							
eGFR											
No change	≥5%	1		PICU admission	1						
0-25%	≥5%	2		Stem cell	3						
			X	transplantation							
25-50%	≥10%	4		Ventilation or use of	5						
				vasoactive agent							
≥0%	≥ 15%	8									

419

For biomarkers (KIM-1, suPAR, NGAL) 4ml of whole blood is collected (same sample as for
sub-study 1) in plain tubes left at room temperature for 10 minutes until clot formation. Later
the sample is centrifuged. The supernatant is then stored at -80 °C as described in sub-study 1.
Concentrations of AKI biomarkers (KIM-1, NGAL, suPAR) will be determined using Luminex
multiplex bead-based array or high-sensitivity ELISAs such as Quantikine® assays as outlined
for sub-study 1.

426

427 2.7.2 Sub-study 2 variables

Sub-study 2 primary outcome variable are the occurrence of KDIGO stage 2 or stage 3 (severe)
AKI on Day 3. Secondary outcome variables are Death, whether a patient required dialysis or
PICU admission and the length of hospital stay.
The sub-study 2 independent variables are the composite Day 1 RAI score, the various patient
baseline clinical features and the baseline (day 1) serum concentrations of NGAL, KIM-1 and
SuPAR.

434

435 2.7.3 Sub-study 2 data analysis

Data will be exported from RedCap TM to an excel spreadsheet and then imported into an IBM
TM-SPSS TM version 29 (IBM Corp., Armonk, NY, USA) database for data analysis in SPSS
version 29. Categorical data will be expressed as frequencies and percentages while continuous
data will be expressed as median and interquartile range if of asymmetric distribution while
data that has a normal distribution will be expressed as means with standard deviation (SD).
The Shapiro-Wilk test will be used to determine data distribution.

To test the association between continuous data and the outcome variable (severe AKI at Day 2 Yes/No), the independent t test (parametric data) or Mann-Whitney test (non-parametric data) will be used. Categorical data will be tested for association to the outcome variable (severe AKI Yes/No), using the Chi-square or Fisher's exact test for cells containing less than five. A $p \le 0.05$ will be considered as being statistically significant.

All variables showing an association to the bivariate form of the outcome variable (severe AKI 448 48hrs later Yes/No) with a probability of less than 25 % (p< 0.25), and all independent variables 449 previously shown to have association with the outcome variable (severe AKI on day 3 of-450 admissions Yes/No) from the literature will be used to construct a multivariate logistic 451 regression model.

The quality of the multivariable models will be assessed using the likelihood-ratio (LR) chisquare test on the models for the global null hypothesis that none of the added potential predictors predicts the dependent variable, the Hosmer and Lemeshow (H&L) goodness-of-fit test, and the C-statistic.

The utility of the renal angina score for predicting MAKI will be assessed using sensitivity, 456 specificity, negative and positive predictive values (NPV and PPV) and estimates of the area 457 under the curve (AUC). Local risk factors as identified from the cohort using multivariate 458 logistic regression will be incorporated into the RAI in order to test if this will improve 459 performance. Youden's index will be used to determine the cut-off point for the modified RAI 460 and curve fitting techniques will be utilized as described in previous studies by Matsuura et 461 al.[57, 58, 59] The AUC of the modified RAI and the AUC obtained from the original RAI will 462 be compared using the z-test (non-parametric). 463

464

465 **2.8 Ethical considerations**

This research is being conducted in compliance with guidelines for good clinical practice and
ethical standards as espoused in the Declaration of Helsinki and the International Declaration
on Human Genetic Data.

469 <u>Permissions:</u> Ethical clearance was sought and obtained from UNZABREC (REF. No. 4269470 2023) and NHRA. Further, the hospital management at CCH and UTHs-CH have granted
471 permission to conduct the study in the two sites respectively.

<u>Informed consent:</u> The study nurse explains the purpose of the study to parents/guardians of
prospective study participants in the language of the participants' choice utilizing an interpreter
where necessary (the interpreter will also co-sign the consent form) and using the study

information sheet for guidance. The study nurse further explains that participation is voluntary
and that participants would be free to withdraw at any time and without explanation if they so
wish and that they will not suffer any punitive measures as a result. The parents/guardians are
offered a copy of the study information sheet in a language of their choice to read through and
follow along. They are also given an opportunity to seek further clarifications or ask questions
and then the study nurse invites them to participate in the study.

If the parent guardian agrees to participate, they are asked to sign the written consent form which is available in Bemba, English, Lozi, Nyanja and Tonga. The signature is witnessed by a person of the parents' choice. The study nurse takes a picture of the signed consent form and uploads it to the study database, gives a copy to the parent/guardian and also keep a copy in a file kept at the study site in the research office at the site.

<u>Assent:</u> For children whose parent/guardian has given written informed consent, and the child
is older than 7 years and able to understand the information presented and is medically able to
assent they are asked to assent by the study nurse in the presence of their parent/guardian.

489 <u>Confidentiality:</u> the interview is conducted in a corner /room away from the main ward. Each 490 participant is assigned a unique study number that is used with the stored data and during the 491 laboratory processing of samples. The screen book with participant data which includes names 492 is kept in a locked cabinet in the site research office. Once the study concludes the logbooks 493 will be held by the overall PI at UTH-CH in a locked cabinet at UTH-CH

<u>494</u> <u>Description of Risks:</u> there are no additional risks associated with participation in the study. 495 Participants experience mild pain during phlebotomy. The risk of infection to injection site 496 during phlebotomy is reduced by sterilizing the site of injection as per standard 497 medical/hospital procedure. These procedures are all conducted by trained health workers 498 (nurse or doctor).

499 <u>Emergency care and insurance for research-related injuries:</u> This is an observational study and 500 so no interventions will be made on participants, and all procedures such as phlebotomy do not 501 represent added risk beyond that which participants undergo during the process of receiving 502 the standard care offered by the hospital. Thus, no insurance is offered to participants.

503 <u>Description of Benefits and anticipated gain in scientific knowledge:</u> There are few direct 504 benefits to participants. At times hospitals do not have functional laboratory consumables to 505 conduct regular blood tests but during the course of the study for all participants baseline blood 506 results are done and made available to the attending doctor. A transport refund is also offered 507 if collection of discharge data may delay the departure of the patient.

508 Much of the anticipated benefit is long term. Information gleaned from this work will shade 509 light on the risks of MAKI in the local Zambian environment and may help clinicians and 510 policy makers to formulate strategies to prevent MAKI in the future.

Also, if the various biomarkers evaluated prove to be able to accurately predict MAKI before it is clinically evident, they may be used to design point- of- care tests that will make diagnosis of MAKI faster and earlier and allow implementation of treatments to mitigate the effects of MAKI in children.

515

516 **3.0 Discussion**

517 **3.1 Study limitations**

518 Since the proposed study is not prospective from point of infection, the recruited patients are 519 at different stages along the disease pathophysiology. This may influence the levels of the

various biomarkers that in turn may act as a confounder affecting the significance that may beattached to the determined risk factors.

522 Moreover, the significance of a specific SNPs in relation to the disease varies frequently across 523 diverse populations and is notably influenced by ethnicity. Many of the SNPs employed in this 524 study were originally characterized in diverse populations, which may result in a lack of 525 association with MAKI. This might lead to a false conclusion that polymorphisms associated 526 with these immune factors have no effect upon the severity of renal involvement in malaria.

It is an accepted fact that the relationship between genetic variation and expression of complex syndromes such as AKI is complex because most of the gene products work within networks in which redundancy, compensatory mechanisms and feedback mechanisms come into play. Thus, the lack of association between an SNP and AKI in an in vivo setting may just be a reflection of this fact.

532

3.2 Data management and quality assurance

Data is captured using a digital form in RedCap TM. Data will be exported to a *Microsoft Excel* version 16.0 (Microsoft Corp, Redmond, WA, USA) spreadsheet and then imported into an IBM TM-SPSS TM version 25 (IBM Corp., Armonk, NY, USA) database for storage and initial data analysis. The database will be securely stored on a password-protected computer, with access restricted to essential research team members, such as the statistician.

Prior to the commencement of participant recruitment, all research team members underwent training on data collection standards, conducted by the Principal Investigator (PI). Throughout the study, the PI will perform weekly reviews of all data entry forms to ensure completeness and accuracy. Any identified errors or missing data will be addressed promptly by consulting

the responsible research team member for correction. All team members have been briefed onthe proper protocols for specimen collection, transportation, and handling.

545 Specimens designated for molecular and genetic analysis will be transported on dry ice in a 546 cooler box from the Clinical Center Hospital (CCH) to the Kaposi's Sarcoma (KS) laboratory, 547 where they will be stored for long-term analysis. The laboratories involved in specimen 548 processing include the KS molecular laboratory and the University of Zambia Veterinary 549 School genetics laboratories. Both laboratories are accredited and recognised as national 550 reference laboratories.

551 Procedures for specimen handling and processing will adhere strictly to established standards.
552 These standards include appropriate labeling, documentation, and storage conditions to
553 maintain specimen integrity throughout the study.

554

555 **3.3 Dissemination plan**

Results of this study will be used to write a thesis in partial fulfilment for the award of the degree of Doctor of Philosophy (PhD) at the University of Zambia. Reports will be presented to the medical library and the university, and a soft copy will be available online. Findings will be published in peer-reviewed journals.

560

561 3.4 Discarding of study materials

Left over blood samples will be kept at -800 C freezer in the KS molecular laboratory at UTH-CH for five years and may be used in future studies examining complicated malaria in children if permission is granted at that time from the ethical review board for an extension of the study.

565

566 **3.5 Projected Timeline**

567 This study is projected to run from 2023 to 2026 as shown in **Table 3**.

568

569 Table 3: Gannt chart

Activity	2023			2024				2025				2026				
	Q	Q	Q	Q	Q	Q	Q	Q	Q	Q	Q	Q	Q	Q	Q	Q
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
Research																
proposal																
Development																
Ethics and																
NHRA approvals																
Sample																
Collection																
Laboratory																
Analysis																
Review paper																
Submitted																
Paper 1																
Submitted																
Paper 2																
submitted																
Paper 3																
Submitted																
Project wind																
down and																

570 Legend: Q= Quater

571

572 Author contributions

573

- 574 Conceptualization: Chisambo Mwaba, Evans Mpabalwani, Sody Munsaka
- 575 Writing original draft: Chisambo Mwaba
- 576 Supervision- Evans Mpabalwani, Sody Munsaka, Mignon McCulloch, Owen Ngalamika

- 577 Writing review & editing: Chisambo Mwaba, Owen Ngalamika, Sody Munsaka, David
- 578 Mwakazanga, David Rutawgwerae, Suzanna Mwanza, Mignon McCulloch, Evans
- 579 Mpabalwani

580

581 Acknowledgments

582 We are grateful to Monica Mweetwa for reviewing the draft manuscript.

583

584 **References**

- 585 1. Cox FE. History of the discovery of the malaria parasites and their vectors. Parasit vectors.
- **586** 2010;3(1):1-9.
- 2. Who. World malaria report 2020: 20 years of global progress and challenges. World Health
- 588 Organization Geneva; 2020. p. 1-151.
- 589 3. Health ZMo. Annual Health Statistical Report 2017-2021 (Tracking the performance of the
- 590 NHSP 2017-2021. Lusaka: Government of the Republic of Zambia Ministry of Health; 2022.
- 4. Batte A, Berrens Z, Murphy K, Mufumba I, Sarangam ML, Hawkes MT, et al. Malaria-
- 592 Associated Acute Kidney Injury in African Children: Prevalence, Pathophysiology, Impact,
- and Management Challenges. Int J Nephrol Renovasc Dis. 2021;14:235-53.
- 594 5. Tembo D, Mwanza S, Mwaba C, Dallah I, wa Somwe S, Seydel KB, et al. Risk factors for
- acute kidney injury at presentation among children with CNS malaria: a case control study.
- 596 Malar J. 2022;21(1):310.
- 597 6. Plewes K, Turner GDH, Dondorp AM. Pathophysiology, clinical presentation, and
- treatment of coma and acute kidney injury complicating falciparum malaria. Curr Opin Infect
- 599 Dis. 2018;31(1):69-77.

- 600 7. Das BS. Renal failure in malaria. J Vector Borne Dis. 2008;45(2):83-97.
- 601 8. White NJ. Severe malaria. Malar J. 2022;21(1):284.
- 602 9. Mwaba C, Munsaka S, Bvulani B, Mwakazanga D, Chiluba BC, Fitzwanga K, et al.
- Malaria is the leading cause of acute kidney injury among a Zambian paediatric renal service
- 604 cohort retrospectively evaluated for aetiologies, predictors of the need for dialysis, and
- 605 outcomes. PLoS One. 2023;18(10):e0293037.
- 10. Anand S, Bitton A, Gaziano T. The gap between estimated incidence of end-stage renal
- disease and use of therapy. PLoS One. 2013;8(8):e72860.
- 11. Mariana Conceição de S, Tatiana Almeida P, Maria das Graças H. Multiple Organ
- 609 Dysfunction During Severe Malaria: The Role of the Inflammatory Response. In: Alfonso
- JR-M, editor. Current Topics in Malaria. Rijeka: IntechOpen; 2016. p. Ch. 5.
- 611 12. Barsoum RS. Malarial acute renal failure. J Am Soc Nephrol. 2000;11(11):2147-54.
- 612 13. Katsoulis O, Georgiadou A, Cunnington AJ. Immunopathology of Acute Kidney Injury in
- 613 Severe Malaria. Front Immunol. 2021;12.
- 614 14. Conroy AL, Hawkes M, Elphinstone RE, Morgan C, Hermann L, Barker KR, et al. Acute
- 615 Kidney Injury Is Common in Pediatric Severe Malaria and Is Associated With Increased
- 616 Mortality. Open Forum Infect Dis. 2016;3(2).
- 15. Namazzi R, Batte A, Opoka RO, Bangirana P, Schwaderer AL, Berrens Z, et al. Acute
- 618 kidney injury, persistent kidney disease, and post-discharge morbidity and mortality in severe
- 619 malaria in children: A prospective cohort study. EClinicalMedicine. 2022;44:101292.
- 620 16. Mousa A, Al-Taiar A, Anstey NM, Badaut C, Barber BE, Bassat Q, et al. The impact of
- 621 delayed treatment of uncomplicated P. falciparum malaria on progression to severe malaria: A

- 622 systematic review and a pooled multicentre individual-patient meta-analysis. PLoS Med.
- 623 2020;17(10):e1003359.
- 624 17. Vasquez M, Zuniga M, Rodriguez A. Oxidative Stress and Pathogenesis in Malaria. Front
- 625 Cell Infect Microbiol. 2021;11.
- 18. Van Avondt K, Nur E, Zeerleder S. Mechanisms of haemolysis-induced kidney injury. Nat
- 627 Rev Nephrol. 2019;15(11):671-92.
- 628 19. Elphinstone RE, Conroy AL, Hawkes M, Hermann L, Namasopo S, Warren HS, et al.
- 629 Alterations in Systemic Extracellular Heme and Hemopexin Are Associated With Adverse
- 630 Clinical Outcomes in Ugandan Children With Severe Malaria. J Infect Dis.
- 631 2016;214(8):1268-75.
- 632 20. Belachew EB. Immune Response and Evasion Mechanisms of Plasmodium falciparum
- 633 Parasites. J Immunol Res. 2018;2018:6529681.
- 634 21. Gomes PS, Bhardwaj J, Rivera-Correa J, Freire-De-Lima CG, Morrot A. Immune Escape
- 635 Strategies of Malaria Parasites. Front Microbiol. 2016;7.
- 636 22. Plewes K, Royakkers AA, Hanson J, Hasan MM, Alam S, Ghose A, et al. Correlation of
- 637 biomarkers for parasite burden and immune activation with acute kidney injury in severe
- 638 falciparum malaria. Malar J. 2014;13:91.
- 639 23. Nguansangiam S, Day NP, Hien TT, Mai NT, Chaisri U, Riganti M, et al. A quantitative
- 640 ultrastructural study of renal pathology in fatal Plasmodium falciparum malaria. Trop Med Int
 641 Health. 2007;12(9):1037-50.
- 642 24. Nayak KC, Kumar S, Gupta BK, Kumar S, Gupta A, Prakash P, et al. Clinical and
- 643 histopathological profile of acute renal failure caused by falciparum and vivax

- 644 monoinfection: an observational study from Bikaner, northwest zone of Rajasthan, India. J
- 645 Vector Borne Dis. 2014;51(1):40-6.
- 646 25. Souza MC, Padua TA, Henriques MG. Endothelial-Leukocyte Interaction in Severe
- 647 Malaria: Beyond the Brain. Mediators Inflamm. 2015;2015:168937.
- 648 26. Ouma BJ, Ssenkusu JM, Shabani E, Datta D, Opoka RO, Idro R, et al. Endothelial
- 649 Activation, Acute Kidney Injury, and Cognitive Impairment in Pediatric Severe Malaria. Crit
- 650 Care Med. 2020;48(9):e734-e43.
- 651 27. Hanson J, Lee SJ, Hossain MA, Anstey NM, Charunwatthana P, Maude RJ, et al.
- 652 Microvascular obstruction and endothelial activation are independently associated with the
- 653 clinical manifestations of severe falciparum malaria in adults: an observational study. BMC

654 Med. 2015;13:122.

655 28. Ortega-Pajares A, Rogerson SJ. The Rough Guide to Monocytes in Malaria Infection.

656 Front Immunol. 2018;9:2888.

- 657 29. Hawkes MT, Leligdowicz A, Batte A, Situma G, Zhong K, Namasopo S, et al.
- 658 Pathophysiology of Acute Kidney Injury in Malaria and Non-Malarial Febrile Illness: A
- 659 Prospective Cohort Study. Pathog. 2022;11(4):436.
- 660 30. Conroy AL, Lafferty EI, Lovegrove FE, Krudsood S, Tangpukdee N, Liles WC, et al.
- 661 Whole blood angiopoietin-1 and-2 levels discriminate cerebral and severe (non-cerebral)
- malaria from uncomplicated malaria. Malar J. 2009;8(1):1-7.
- 663 31. Jaber BL, Liangos O, Pereira BJG, Balakrishnan VS. Polymorphism of
- Immunomodulatory Cytokine Genes: Implications in Acute Renal Failure. Blood Purific.
 2004;22(1):101-11.

- 32. Jaber BL, Pereira BJ, Bonventre JV, Balakrishnan VS. Polymorphism of host response
- 667 genes: implications in the pathogenesis and treatment of acute renal failure. Kidney Int.
- **668** 2005;67(1):14-33.
- 669 33. Hill AV. The immunogenetics of resistance to malaria. Proc Assoc Am Physicians.
- **670** 1999;111(4):272-7.
- 34. Penha-Gonçalves C. Genetics of Malaria Inflammatory Responses: A Pathogenesis
 Perspective. Front Immunol. 2019;10:1771.
- 673 35. Driss A, Hibbert JM, Wilson NO, Iqbal SA, Adamkiewicz TV, Stiles JK. Genetic
- polymorphisms linked to susceptibility to malaria. Malar J. 2011;10:271.
- 675 36. Dhangadamajhi G, Kar A, Rout R, Dhangadamajhi P. A meta-analysis of TLR4 and TLR9
- 676 SNPs implicated in severe malaria. Rev Soc Bras Med Trop. 2017;50(2):153-60.
- 677 37. Hayek SS, Leaf DE, Samman Tahhan A, Raad M, Sharma S, Waikar SS, et al. Soluble
- Urokinase Receptor and Acute Kidney Injury. N Engl J Med. 2020;382(5):416-26.
- 679 38. Griffin BR, Gist KM, Faubel S. Current Status of Novel Biomarkers for the Diagnosis of
- Acute Kidney Injury: A Historical Perspective. J Intensive Care Med. 2020;35(5):415-24.
- 681 39. Basu RK, Zappitelli M, Brunner L, Wang Y, Wong HR, Chawla LS, et al. Derivation and
- validation of the renal angina index to improve the prediction of acute kidney injury in
- critically ill children. Kidney Int. 2014;85(3):659-67.
- 40. Health ZMo. Zambia Malaria Indicator Survey.: Government of the Republic of Zambia,
 Ministry of Health; 2021.
- 686 41. Moussiliou A, Alao MJ, Denoeud-Ndam L, Tahar R, Ezimegnon S, Sagbo G, et al. High
- 687 Plasma Levels of Soluble Endothelial Protein C Receptor Are Associated With Increased
- Mortality Among Children With Cerebral Malaria in Benin. J Infect Dis. 2014;211(9):1484-8.

- 689 42. Gwer S, Newton CR, Berkley JA. Over-diagnosis and co-morbidity of severe malaria in
- African children: a guide for clinicians. Am J Trop Med Hyg. 2007;77(6 Suppl):6-13.
- 43. Severe malaria. Trop Med Int Health. 2014;19 Suppl 1:7-131.
- 44. Oshomah-Bello EO, Esezobor CI, Solarin AU, Njokanma FO. Acute Kidney Injury in
- 693 Children with Severe Malaria Is Common and Associated with Adverse Hospital Outcomes. J
- 694 Trop Pediatr. 2020;66(2):218-25.
- 45. Narsaria N, Mohanty C, Das BK, Mishra SP, Prasad R. Oxidative stress in children with
 severe malaria. J Trop Pediatr. 2012;58(2):147-50.
- 46. Nagamine Y, Hayano M, Kashiwamura S-i, Okamura H, Nakanishi K, Krudsod S, et al.
- 698 Involvement of interleukin-18 in severe Plasmodium falciparum malaria. Trans R Soc Trop
- 699 Med Hyg. 2003;97(2):236-41.
- 47. Elhussein AB, Huneif MA, Naeem A, Fadlelseed OE, Babiker WG, Rahma NE, et al.
- 701 Correlation of interleukin-4 levels with Plasmodium falciparum malaria parasitaemia in
- 702 Sudanese children. Acta Clin Belg. 2015;70(6):414-8.
- 48. Peyron F, Burdin N, Ringwald P, Vuillez JP, Rousset F, Banchereau J. High levels of
- circulating IL-10 in human malaria. Clin Exp Immunol. 1994;95(2):300-3.
- 49. Lyke K, Burges R, Cissoko Y, Sangare L, Dao M, Diarra I, et al. Serum levels of the
- proinflammatory cytokines interleukin-1 beta (IL-1β), IL-6, IL-8, IL-10, tumor necrosis
- factor alpha, and IL-12 (p70) in Malian children with severe Plasmodium falciparum malaria
- and matched uncomplicated malaria or healthy controls. Infect immun. 2004;72(10):5630-7.
- 50. Kwiatkowski D, Sambou I, Twumasi P, Greenwood B, Hill A, Manogue K, et al. TNF
- concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum
- 711 malaria. The Lancet. 1990;336(8725):1201-4.

712	51. Chaivaro	i SC.	Rutta AS.	Muenthaisong	Κ.	Watkins P.	Na	Ubol M.	Looareesuwan S	S.
			1	111 CONTRACTORING		The second secon	1	0001111	Looureesa nam .	

- 713 Reduced levels of transforming growth factor-beta1, interleukin-12 and increased migration
- inhibitory factor are associated with severe malaria. Acta Trop. 2004;89(3):319-27.
- 52. Lovegrove FE, Tangpukdee N, Opoka RO, Lafferty EI, Rajwans N, Hawkes M, et al.
- 716 Serum angiopoietin-1 and-2 levels discriminate cerebral malaria from uncomplicated malaria
- and predict clinical outcome in African children. PloS one. 2009;4(3):e4912.
- 53. Howie SR. Blood sample volumes in child health research: review of safe limits. Bull
- 719 World Health Organ. 2011;89(1):46-53.
- 720 54. Zambia MoHo. Dried Blood Spot for DNA PCCR Testing. 1 ed. Lusaka: Ministry of

721 Health; 2007.

- 55. Organization WH. The treatment of diarrhoea: a manual for physicians and other senior
 health workers. World Health Organization; 2005. Report No.: 9241593180.
- 56. Selewski DT, Cornell TT, Lombel RM, Blatt NB, Han YY, Mottes T, et al. Weight-based
- determination of fluid overload status and mortality in pediatric intensive care unit patients
- requiring continuous renal replacement therapy. Intensive Care Med. 2011;37(7):1166-73.
- 57. Matsuura R, Srisawat N, Claure-Del Granado R, Doi K, Yoshida T, Nangaku M, et al. Use

of the Renal Angina Index in Determining Acute Kidney Injury. Kidney Int Rep.

729 2018;3(3):677-83.

- 58. Matsuura R, Iwagami M, Moriya H, Ohtake T, Hamasaki Y, Nangaku M, et al. A Simple
- 731 Scoring Method for Predicting the Low Risk of Persistent Acute Kidney Injury in Critically
- 732 Ill Adult Patients. Sci Rep. 2020;10(1):5726.

- 59. Zulu C, Mwaba C, Wa Somwe S. The renal angina index accurately predicts low risk of
- developing severe acute kidney injury among children admitted to a low-resource pediatric
- 735 intensive care unit. Ren Fail. 2023;45(2):2252095.

736

737 Supporting information

- 738 S1 effect sizes and estimation of sample size
- 739 S2 List of primer sequences